ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Researchers identify new drug class with potential in BRCA-mutated tumours
June 21, 2021Researchers from the The Institute of Cancer Research, London and Artios have identified a new class of drugs – POLQ inhibitors – which could have potential for patients with BRCA-mutated tumours. -
Artios, Novartis form cancer therapies collaboration
April 08, 2021Artios Pharma and Novartis have formed a global research collaboration to discover and validate next generation DNA damage response (DDR) targets to enhance the Swiss drugmaker's radioligand therapies (RLT). -
Artios bags $84M to trial next-generation DNA damage response drugs
August 13, 2018Artios Pharma has raised $84 million (£65 million) to take DNA damage response (DDR) programs to clinical proof of concept. The series B round sees more big-name investors give cash to researchers whose earlier work on PARP inhibitor Lynparza put DDR on t
Pharma Sources Insight January 2025
